<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03373968</url>
  </required_header>
  <id_info>
    <org_study_id>DSC/14/2357/51</org_study_id>
    <nct_id>NCT03373968</nct_id>
  </id_info>
  <brief_title>Givinostat in Duchenne's Muscular Dystrophy Long-term Safety and Tolerability Study</brief_title>
  <official_title>Open Label, Long-term Safety, Tolerability, and Efficacy Study of GIVINOSTAT in All DMD Patients Who Have Been Previously Treated in One of the GIVINOSTAT Studies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Italfarmaco</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cromsource</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Italfarmaco</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label, long-term safety, tolerability, and efficacy study of GIVINOSTAT in&#xD;
      all DMD (Duchenne's muscular dystrophy) patients who have been previously treated in one of&#xD;
      the GIVINOSTAT studies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      GIVINOSTAT oral suspension (10 mg/mL) has to be administered orally as 2 oral doses daily&#xD;
      while the subject is in a fed state. The starting dose of GIVINOSTAT in the present long term&#xD;
      study will be the same that the subject was receiving at the end of the previous DMD&#xD;
      GIVINOSTAT study.&#xD;
&#xD;
      As weight affects GIVINOSTAT exposures, the dosage will be modified based on subject weight&#xD;
      according the rules detailed in the study protocol section 11.2.2.1.&#xD;
&#xD;
      In addition, in case a subject will have a consistent (e.g., at least 2 consecutive&#xD;
      evaluations) platelets count ≤150 x 10^9/L and not meet the stopping criteria for platelets,&#xD;
      the Investigator will have to reduce the dose of 1/3 or 20% less of the current dose as&#xD;
      described in the study protocol section 10.5.1.3. During the first month of treatment,&#xD;
      platelets count assessment will be performed weekly, while during the second month it will be&#xD;
      performed every 2 weeks, in order to strictly monitor this parameter for safety reasons, with&#xD;
      the exclusion of subjects coming from study DSC/11/2357/43 for which the first visit will be&#xD;
      4 months after the Visit 1/baseline visit.&#xD;
&#xD;
      Study drug should be permanently interrupted if any of the following occurs:&#xD;
&#xD;
        -  severe drug-related diarrhoea (i.e., increase of ≥7 stools per day);&#xD;
&#xD;
        -  any drug-related SAE;&#xD;
&#xD;
        -  QTcF &gt;500 msec;&#xD;
&#xD;
        -  platelets count ≤50 x 10^9/L;&#xD;
&#xD;
        -  white blood cells ≤2.0 x 10^9/L;&#xD;
&#xD;
        -  hemoglobin ≤8.0 g/dL; To avoid laboratory errors and anomalous values, test must be&#xD;
           confirmed with a repeated test performed on the next working day. The treatment should&#xD;
           be stopped until the retest result becomes available. If the repeated test is still&#xD;
           under the stopping limit value, study drug must be permanently discontinued. If the&#xD;
           repeated test is acceptable, the subject can resume treatment.&#xD;
&#xD;
      The Investigator will follow up the patient until resolution or acceptable stabilization of&#xD;
      the event occurs and document all the relevant information, as applicable. After the&#xD;
      resolution/stabilization of the event, the subject will be withdrawn from the study and the&#xD;
      EOS Visit (see Section 12.1.10) will be performed.&#xD;
&#xD;
      Any decision relevant to the dose adjustment and/or modification of schedule of assessments&#xD;
      can be discussed with the Medical Monitor, but the final decision remains with the&#xD;
      Investigator only or its authorized designee.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">October 24, 2017</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Type, incidence, and severity of treatment related/not related adverse events(AEs) and serious adverse event (SAEs)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">183</enrollment>
  <condition>Duchenne Muscular Dystrophy</condition>
  <arm_group>
    <arm_group_label>givinostat</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Givinostat oral suspension (10 mg/mL) twice daily in a fed state</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Givinostat</intervention_name>
    <description>suspension of givinostat (10 mg/mL)</description>
    <arm_group_label>givinostat</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Must have participated in one of the previous studies with GIVINOSTAT in DMD and have&#xD;
             attended the End of Study Visit or must have been screened in study DSC/14/2357/48 and&#xD;
             met:&#xD;
&#xD;
               -  all the inclusion criteria and none of the exclusion criteria,&#xD;
&#xD;
               -  had a baseline vastus lateralis muscle fat fraction (VL MFF) assessed by MRS in&#xD;
                  the range ≤5% or &gt;30%, i.e. included in&quot;off-target&quot; group,&#xD;
&#xD;
               -  never been randomized because, the enrollment in the off target group was&#xD;
                  completed.&#xD;
&#xD;
          2. Aged ≥6 years old;&#xD;
&#xD;
          3. Are able to give informed assent and/or consent in writing signed by the subject&#xD;
             and/or parent/legal guardian (according to localregulations);&#xD;
&#xD;
          4. Subjects must be willing to use adequate contraception:&#xD;
&#xD;
               -  Contraceptive methods must since the previous GIVINOSTAT study through 3 months&#xD;
                  after the last dose of study drug, and include the following:&#xD;
&#xD;
                    -  True abstinence (absence of any sexual intercourse), when in line with the&#xD;
                       preferred and usual lifestyle of the subject.&#xD;
&#xD;
                    -  Periodic abstinence (e.g. calendar, ovulation, symptothermal, postovulation&#xD;
                       methods) and withdrawal are not acceptable methods of contraception.&#xD;
&#xD;
                    -  Condom with spermicide and the female partner must use an acceptable method&#xD;
                       of contraception, such as an oral,&#xD;
&#xD;
                    -  transdermal, injectable or implanted steroid-basedcontraceptive, or a&#xD;
                       diaphragm or a barrier method of contraception in conjunction with&#xD;
                       spermicidal jelly such asfor example cervical cap with spermicide jelly.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Use of any pharmacologic treatment, other than corticosteroids, that might have had an&#xD;
             effect on muscle strength or function within 3 months prior to be enrolled in this&#xD;
             study (e.g., growth hormone); Vitamin D, calcium, and any other supplements will be&#xD;
             allowed;&#xD;
&#xD;
          2. Use of any current investigational drug other than Givinostat;&#xD;
&#xD;
          3. Have presence of other clinically significant disease, which, in the Investigator's&#xD;
             opinion, could adversely affect the safety of the subject, making it unlikely that the&#xD;
             course of treatment or follow-up would be completed, or could impair the assessment of&#xD;
             study results;&#xD;
&#xD;
          4. Have a diagnosis of other uncontrolled neurological diseases or presence of relevant&#xD;
             uncontrolled somatic disorders that are not related to DMD;&#xD;
&#xD;
          5. Have platelets count, White Blood Cell and Hemoglobin at screening &lt; Lower Limit of&#xD;
             Normal (LLN)* (for abnormal screening laboratory test results (&lt;LLN), the platelets&#xD;
             count, White Blood Cell and Hemoglobin will be repeated once; if the repeat test&#xD;
             result is still &lt;LLN, then exclusionary);&#xD;
&#xD;
          6. Have Triglycerides &gt; 300 mg/dL (3.42 mmol/L) in fasting condition at screening visit*&#xD;
             (for abnormal screening laboratory test results (&gt;300 mg/dL), the triglycerides will&#xD;
             be repeated once; if the repeat test result is still &gt;300 mg/dL, then exclusionary);&#xD;
&#xD;
          7. Have inadequate renal function, as defined by serum Cystatin C &gt;2 x the upper limit of&#xD;
             normal (ULN) at screening visit*. If the value is &gt;2 x ULN, the serum Cystatin C will&#xD;
             be repeated once; if the repeated test result is still &gt;2 x ULN, the subject should be&#xD;
             excluded);&#xD;
&#xD;
          8. Have heart failure (New York Heart Association Class III or IV)&#xD;
&#xD;
          9. Have a current liver disease or impairment, including but not limited to an elevated&#xD;
             total bilirubin* (i.e. &gt; 1.5 x ULN), unless secondary to Gilbert disease or pattern&#xD;
             consistent with Gilbert's;&#xD;
&#xD;
         10. Have a baseline QTcF &gt;450 msec, (as the mean of 3 consecutive readings 5 minutes&#xD;
             apart) or history of additional risk factors for torsades de pointes (e.g., heart&#xD;
             failure, hypokalemia, or family history of long QT syndrome);&#xD;
&#xD;
         11. Have a psychiatric illness/social situation rendering the potential subject unable to&#xD;
             understand and comply with the muscle function tests and/or with the study protocol&#xD;
             procedures.&#xD;
&#xD;
         12. Have any hypersensitivity to the components of study medication;&#xD;
&#xD;
         13. Have a sorbitol intolerance or sorbitol malabsorption or have the hereditary form of&#xD;
             fructose intolerance.&#xD;
&#xD;
               -  the Investigators to evaluate these exclusion criteria can use the laboratory&#xD;
                  results obtained within 5 months from V1, to allow the continuity of the&#xD;
                  treatment. It is worth noting, as soon as the site will receive the laboratory&#xD;
                  results done in screening/baseline (Visit 1) visit they will check the GIVINOSTAT&#xD;
                  dose and modify it as per protocol safety rules and/or dosage modifications&#xD;
                  rules.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of California - Davis Medical Center - Devis Physical Medicine &amp; Rehabilitation</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rady Children's Hospital center - UCSD Department of Neuroscience</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Connecticut Children's Medical Center, Neurology Division</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Child Health Research Institute</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Rare Disease Research, LLC</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30318</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa Children's Hospital</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine in St Louis Department of Neurology 660 S.Euclid Avenue, Campus Box 8111</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shriners Hospitals for Children</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital of Philadelphia Colket Translational Research Building</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University Childrens Hospital of Richmond at</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals Leuven, Neuromuscular Reference Centre, Child Neurology</name>
      <address>
        <city>Leuven</city>
        <zip>03000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de La Citadelle, Centre de Référence des Maladies Neuromuscolaires (CRMN)</name>
      <address>
        <city>Liège</city>
        <zip>04000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kinsmen Research Centre - Alberta Children's Hospital</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T3B 6A8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of British Columbia, Children's and Womens Health Centre of BC Branch</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6H 3V4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holland Bloorview Kids Rehabilitation Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4G1R8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes - Hotel-Dieu - Hopital Nord Laennec, rez-de-chausse haut ail Ouest</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Armand Trousseau I-Motion - Plateforme d'essais cliniques pédiatriques Bâtiment Lemariey - Porte 20 * 2ème étage 26 Avenue du Dr Arnold Nette</name>
      <address>
        <city>Paris</city>
        <zip>760</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen - Kinder-und Jugendmedizin Neuropadiatrie</name>
      <address>
        <city>Essen</city>
        <zip>D-45147</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik- und Poliklinik fur Kinder- und Jugendmedizin, Universitatsklinikum HamburgEppendorf, Martinistr. 52</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universitat Munchen, Campus Innenstadt, Lindwurmstr. 4</name>
      <address>
        <city>München</city>
        <zip>80337</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O.S.D. Centro Traslazionale di Miologia e Patologie Neurodegenerative, Building 16 - ground floor IRCCS Istituto Giannina Gaslini,</name>
      <address>
        <city>Genova</city>
        <zip>16147</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O.U. Policlinico G. Martino, U.O.C. Neurologia e Malattie Neuromuscolari</name>
      <address>
        <city>Messina</city>
        <zip>98125</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Istituto Neurologico Carlo Besta</name>
      <address>
        <city>Milano</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Clinico NeMO Fondazione Serena ONLUS Area SUD</name>
      <address>
        <city>Milano</city>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, UOS di Neurologia Pediatrica</name>
      <address>
        <city>Milan</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Pediatrico Bambino Gesù, Malattie Neuromuscolari e Neurodegenerative</name>
      <address>
        <city>Roma</city>
        <zip>00146</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione Policlinico Universitario &quot;A.Gemelli&quot;, UOC Neuropsichiatria Infantile</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Center LUMC, Albinusdreef 2</name>
      <address>
        <city>Leiden</city>
        <zip>2300</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radboud University Medical Centre</name>
      <address>
        <city>Nijmegen</city>
        <zip>6500</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic of Neurology and Psychiatry for Children and Youth - Neurology Department Dr. Subotic 6a,</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neuromuscular Pathology Unit - Hospital Sant Joan de Déu</name>
      <address>
        <city>Esplugues De Llobregat</city>
        <state>Barcellona</state>
        <zip>08950</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Materno-Infantil</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocio</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari i Politècnic La Fe - Servicio Neurologia</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alder Hey Children's Hospital NHS Trust</name>
      <address>
        <city>Liverpool</city>
        <state>UK</state>
        <zip>L12 2AP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Robert Jones and Agnes Hunt Orthopaedic Hospital NHS Foundation Trust</name>
      <address>
        <city>Gobowen</city>
        <zip>SY10 7AG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCL Great Ormond Street Institute of Child Health, Dubowitz Neuromuscular Centre and MRC Centre for NMD</name>
      <address>
        <city>London</city>
        <zip>, WC1N 1EH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The John Walton Muscular Dystrophy Research Centre</name>
      <address>
        <city>Newcastle Upon Tyne</city>
        <zip>NE1 3BZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Serbia</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>December 4, 2017</study_first_submitted>
  <study_first_submitted_qc>December 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 14, 2017</study_first_posted>
  <last_update_submitted>July 30, 2021</last_update_submitted>
  <last_update_submitted_qc>July 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Dystrophies</mesh_term>
    <mesh_term>Muscular Dystrophy, Duchenne</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

